C the Signs

C the Signs is an AI-powered cancer prediction platform that helps primary care clinicians identify patients at risk of cancer at the earliest, most treatable stage. The system analyses data already present in patient electronic health records — going beyond age and gender to weigh hundreds of clinical signs, symptoms and risk factors — and recommends the most appropriate test or specialist referral in under 30 seconds.

The company was founded in 2017 by NHS doctors Bea Bakshi and Miles Payling and now works with over 3,000 doctors across the UK. Its AI model has identified more than 25,000 cancers across over 50 cancer types, including detecting 20.7% of breast cancers up to five years earlier than standard pathways and improving early-stage ovarian cancer detection by 53.3% compared to traditional methods. A 2025 study using Mayo Clinic data showed colorectal cancer detection sensitivity of 93.8%, comparable to colonoscopy.

C the Signs raised a $8 million round from Khosla Ventures in January 2025 to fund its U.S. expansion, having previously raised £5 million in Series A from MMC Ventures, Ataraxia and Acequia Capital alongside angels including the founder of Monzo and former CEOs of Bupa and AXA Health. The company is a founding member of the CancerX White House Cancer Moonshot.